NCT06222879View on ClinicalTrials.gov

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

HRS-8080; SHR-A1811

Participants will receive HRS-8080 and SHR-A1811

DRUG

HRS-8080; SHR-A2009

Participants will receive HRS-8080 and SHR-A2009

DRUG

SHR-A2009; SHR-1316

Participants will receive SHR-A2009 and SHR-1316

Trial Locations (1)

410031

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY